Participating Institutions & Investigators

Maysa Abu-Khalaf, MD is Associate Professor Of Medicine at Thomas Jefferson University as well as Director, Breast Medical Oncology Program and Co-Director, Breast Care Center.

Dr. Abu-Khalaf graduated from the Univ of Jordan, Fac of Med, Amman, Jordan in 1995. She works in Philadelphia, PA and one other location and specializes in Medical Oncology. Dr. Abu-Khalaf is affiliated with Deborah Heart & Lung Center, Lankenau Medical Center, Thomas Jefferson University Hospital and Yale New Haven Hospital. She did a Fellowship at Yale-New Haven Hospital in New Haven, CT, her Residency at Jordan University Hospital and Internship at Norwalk Hospital, Norwalk CT. She is Board Certified in Medical Oncology.

Jefferson University Hospitals and Thomas Jefferson University are partners in providing excellent clinical and compassionate care for our patients in the Philadelphia region, educating the health professionals of tomorrow in a variety of disciplines and discovering new knowledge that will define the future of clinical care. Jefferson has topped the list of hospitals in Pennsylvania (3rd) and the Philadelphia metro area (2nd) in U.S.News & World Report’s annual listing of the best hospitals and specialties. Learn more at: http://hospitals.jefferson.edu/about-us.html.

Dr. Brown-Glaberman holds a Doctor of Medicine from The University of New Mexico School of Medicine where she also completed a research fellowship in the Department of Pathology. She completed her internship, residency and hematology / oncology fellowship at the University of Arizona in Tucson, Arizona. Dr. Brown-Glaberman returned to her home state and to the University of New Mexico Comprehensive Cancer Center in 2013. Her interests are centered on the treatment of solid tumors, particularly breast cancer. Her research focuses on the development of prognostic and predictive biomarkers to guide the use of novel therapies. She co-leads the Breast Cancer Clinical Working Group and leads the Breast Protocol Development Subgroup at the UNM Cancer Center. Dr. Brown-Glaberman actively participates in NCI-sponsored clinical trials and is the Institutional Principal Investigator for numerous NCI cooperative group studies. Since her arrival in 2013, Dr. Brown-Glaberman has also driven the UNM Cancer Center Breast Clinical Working Group investigator-initiated clinical trial efforts.

The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. . The 130 cancer research scientists affiliated with the UNMCCC were awarded almost $60 million in federal and private grants and contracts for cancer research projects and published 301 high quality publications. Promoting economic development, they filed more than 30 new patents in FY16, and since 2010, have launched 11 new biotechnology start-up companies. Scientists associated with the UNMCCC Cancer Control & Disparities have conducted more than 60 statewide community-based cancer education, prevention, screening, and behavioral intervention studies involving more than 10,000 New Mexicans. Finally, the physicians, scientists and staff have provided education and training experiences to more than 230 high school, undergraduate, graduate, and postdoctoral fellowship students in cancer research and cancer health care delivery. Learn more at  cancer.unm.edu

Dr. Pavani Chalasani, MD, MPH, Assistant Professor of Medicine Divisions of Hematology-Oncology at the University of Arizona Cancer Center.

She attended medical school at Gandhi Medical College, Hyderabad, India and received her Master’s Degree in Public Health from University of Massachusetts, Amherst. She completed her internal medical residency followed by fellowship in Hematology-Oncology at University of Arizona where she served as chief fellow during her final year of fellowship. Subsequently, she joined the breast medical oncology team at the University of Arizona Cancer Center. She is one of seven junior faculty members to receive the inaugural Arizona Health Sciences Center Career Development Award which was designed to provide research training and funding opportunities for up to two years to foster an academic career in clinical and translational research.

She is the institutional Principal Investigator (PI) on multiple industry sponsored, and co-operative group protocols, and PI for several investigator-initiated clinical trials. She is a member of UACC’s Scientific Review Committee which is responsible for critiquing and approving clinical trials. She has active collaborations with members in cancer biology, cancer prevention, and cancer imaging groups and have several ongoing investigator-initiated trials designed to better understand breast cancer biology and to develop predictive biomarkers.

Since being established in 1976, the University of Arizona Cancer Center has worked to prevent and cure cancer. The Cancer Center is one of 41 comprehensive cancer centers in the nation and the only one headquartered in and serving the entire state of Arizona that has been designated by the National Cancer Institute as a Comprehensive Cancer Center, the NCI’s highest designation. That designation is reserved for centers focusing on patient care as well as basic and clinical research, prevention, education, outreach and training. The Cancer Center has an NCI Specialized Program of Research Excellence (SPORE) grant for gastrointestinal cancers and it also has a SPORE for lymphatic cancers. The Cancer Center is a leader in research on women’s cancers (breast, ovarian), men’s cancers (prostate), gastrointestinal cancers (colon, pancreas and liver), lymphoma and skin cancers and is home to one of the largest Cancer Prevention and Control Programs among the nation’s comprehensive cancer centers, with leading prevention research in breast, colon, lung, prostate and skin cancers. With primary locations at the University of Arizona in Tucson and St. Joseph’s Hospital and Medical Center in Phoenix, the Cancer Center has more than a dozen research and education offices in Phoenix and throughout the state and affiliate sites in Mexico and Colorado. The University of Arizona Medical Center is the Cancer Center’s clinical affiliate in Tucson. Our patients are treated in multidisciplinary clinics by teams of physicians and health care professionals who are experts in their specialties. Our cross-discipline approach means our patients get the best treatment possible: treatment tailored to them. Construction has begun on The University of Arizona Cancer Center’s 220,000-square-foot outpatient clinic and research building on the Phoenix Biomedical Campus. The five-story facility will be located at the northwest corner of North Seventh and East Fillmore streets in downtown Phoenix, and the building is scheduled to be open for patient care in 2015. The University of Arizona Cancer Center is partnering with St. Joseph’s Hospital and Medical Center in Phoenix to provide inpatient cancer care, and the Cancer Center is providing outpatient oncology services at St. Joseph’s Hospital, continuing there until the new clinic is open. The Cancer Center’s 73 research labs and more than 300 nationally and internationally renowned physician and scientist members work to bring the power of research to cancer prevention and treatment through a direct link between the latest research discoveries and patient care. Twenty-two Cancer Center-affiliated physicians are included in the 2013 Best Doctors in America database. Learn more at  azcc.arizona.edu.

Dr. Carla Falkson is the Director of the Breast Oncology Clinical Research Program and Breast Cancer Service Line and Leader, Breast Cancer Unit in Medical Oncology at the UR Medicine Wilmot Cancer Institute. She is also the Medical Director of Pluta Cancer Center.

Dr. Falkson’s research is focused on developing innovative treatments for patients with breast cancer. For the past three decades, she has been actively involved in the development and planning of clinical trials using new agents, including genomic and other translational approaches such as circulating tumor DNA, to improve the selection of patients for specific treatments and thus improving the outcome for patients. As a seasoned investigator, she has led the Eastern Co-operative Group Research at her previous two institutions and now continues this legacy of excellence at the University of Rochester Medical Center.

Dr. Falkson’s philosophy is to understand the patient and his or her disease. She believes it is important to listen to a patient and hear their needs especially since their cancers, despite similarities, are all unique and need different approaches for treatment. She has a special interest in treating HER2 amplified (over-expressed), hormone receptor-positive breast cancer, and treatment modalities for optimal bone health in breast cancer patients.

She received her MBCHB from the University of Pretoria in 1982 and continued with Post-doctoral Training & Residency 1989 – 1994. She did a fellowship in Hematology/Oncology at University of Pretoria, and a fellowship in Medical Oncology at M.D. Anderson Cancer Center. Her awards include the, Unsung Hero Award from University of Alabama 2017.

Ruth O’Regan, M.D., chief of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin, has been named the next Charles A. Dewey Professor and Chair of Medicine at the University of Rochester Medical Center’s School of Medicine and Dentistry, pending approval by the University Board of Trustees. Dr. O’Regan brings more than 20 years of experience in academic medicine and a distinguished history of research and publication to her new role.

Dr. O’Regan is an internationally recognized breast-cancer physician and researcher with particular expertise on breast cancers that are resistant to current therapies.

A native of Dublin, Ireland, O’Regan previously was a professor of hematology and medical oncology at Emory University, where she held the Louisa and Rand Glenn Family Chair in Breast Cancer Research. Additionally, O’Regan was the medical director at Glenn Family Breast Center of Emory University, director of the Breast Cancer Translational Research Program at the Winship Cancer Institute, and chief of hematology and medical oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital.

In her dedication to training the next generation of physicians, O’Regan served as vice chair for educational affairs in the department of hematology and medical oncology and as director of the hematology/oncology fellowship program at Emory University.

With a highly active research program focused on identifying mechanisms of resistance to breast-cancer therapies and development of new therapies, O’Regan has been principal investigator for numerous grants and clinical trials.

Her research group has made significant discoveries about the role of the PI3 Kinase-mTOR pathway in triple-negative breast cancer, showing that mTOR inhibition can sensitize breast-cancer cells to upstream growth-factor inhibitors. These discoveries resulted in a novel clinical trial for patients with metastatic breast cancer.

The University of Rochester Medical Center (URMC) is one of the nation’s leading academic medical centers. It forms the centerpiece of the University of Rochester’s health research, teaching and patient care missions.

The University of Rochester Medical Center is a private, coeducational, nonsectarian, and nonprofit research university.

The medical center includes Strong Memorial Hospital, the Eastman Institute for Oral Health, the University of Rochester School of Medicine and Dentistry, with its faculty practice (University of Rochester Medical Faculty Group), and the University of Rochester School of Nursing.

URMC was one of the first 12 academic medical centers to receive a Clinical and Translational Science Award from the National Institutes of Health and has been continually funded by this grant for a total of $86 million. The University also was awarded a one-in-the-nation $19 million grant to coordinate more than 50 of the top academic medical centers in the nation that are part of the Clinical and Translational Science Awards Program. Learn more at urmc.rochester.edu

Dr. Augustin Garcia is a medical oncologist who practices at Louisiana State University and holds the position of Section Chief and Professor, School of Medicine, Department of Medicine Hematology Oncology. Dr. Garcia specializes in the management of women’s cancers (breast, ovary, uterus and cervix). He works closely with breast surgeons, gynecologist oncologists, radiation oncologists, radiologists, plastic surgeons, nurses, dietitians, genetic counselors, and physical and occupational therapists to provide the best possible, comprehensive and personalized care for women’s cancers.

In addition to providing state of the art medical care to his patients, Dr. Garcia is committed to improving the prognosis and the quality of life of cancer patients and survivors while decreasing the toxicity and side effects associated with current treatments. Dr. Garcia’s practice focuses not only in conventional medical therapies (chemotherapy, surgery and radiation) but follows instead a more integrative approach by introducing complementary medical therapies when indicated.

Dr. Garcia is originally from Mexico and earned his medical degree from Universidad Anahuac in Mexico City. He completed his internship and residency training in internal medicine at the University of Illinois and a fellowship in medical oncology at the University of Southern California. He is board certified in medical oncology. He had a fellowship at LAC+USC Medical Center in Medical Oncology, 1994 – 1997. Dr. Garcia joined LSU in 2015 where he holds the Charles W McMullin III and Richard Paul Grace Chair in Cancer Research.

Dr. Garcia’s primary clinical and research interests focus on women’s cancers (particularly breast and ovarian cancers) and drug development. He is a member of the Breast Cancer Working Group in the Southwest Oncology Group and the Cervical Cancer Task Force from the Gynecologic Cancer Scientific Steering Committee of the National Cancer Institute.

Dr. Garcia is conducting studies in breast and ovarian cancer, evaluating new agents with novel mechanisms of action. He is also a member of several national and international organizations. His work has been published in various journals, such as the Journal of Clinical Oncology and Gynecologic Oncology. He is a frequent speaker at local, national and international events.

He has received awards in Fellowship Award for Outstanding Achievement in Cancer Research, USC Norris; Comprehensive Cancer Center/Pharmacia & Upjohn, 1996; Poster Finalist, ACP Clinical Vignette Competition, Washington, 1993; Intern of the Year, University of Illinois at Urbana-Champaign, 1992; Merit Award, GR 72, Mexico City, 1990.

Since its inception some 75 years ago, the school of medicine has maintained a deep commitment to serving all patients, particularly the underserved. We are aligned with the LSUHSC Health Care Services Division which consists of nine hospitals throughout the state. Through this important relationship, our faculty and house staff provide quality medical care to the residents of Louisiana regardless of income or insurance coverage. Simultaneously, our partnerships with the LSU Healthcare Network and local private hospitals supply outstanding care to a growing population of private patients. These wide ranging medical services support the people of our state while providing the backdrop for a broad and comprehensive clinical education for our students and residents in training. In addition, LSU is home to the Stanley S. Scott Cancer Center (SSSCC) a multidisciplinary organization whose researchers and clinicians apply a range of expertise to cancer research, education, and patient care.
Learn more at  LSUHSC

Dr. William J. Gradishar, M.D., F.A.C.P. is professor of medicine in the division of hematology and medical oncology, department of medicine, at the Feinberg School Medicine at Northwestern University in Chicago, Illinois.

His research focuses on the development of the latest therapies for breast cancer treatment. He has published numerous articles in the area of breast cancer therapy, with a focus on new endocrine therapy and chemotherapy.

After receiving his medical degree from the University of Illinois Abraham School of Medicine in Chicago, he completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago. He then went on to a fellowship in medical oncology at the University of Chicago. He is Board Certified in Internal Medicine, Medical Oncology.

Dr. Gradishar is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He also serves as director of breast medical oncology, associate director of the Lynn Sage Comprehensive Breast Program, and program director of Northwestern University’s Hematology/Oncology Fellowship Training Program.

In addition, he is a Fellow of the American College of Physicians, a member of the American Association for Cancer Research and the American Federation for Clinical Research. He chairs the Oncology Training Program Committee of the American Society of Clinical Oncology (ASCO) and serves on numerous breast cancer committees in other major oncology organizations. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the FDA.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. In 1853, the founders purchased a 379-acre tract of land on the shore of Lake Michigan 12 miles north of Chicago. They established a campus and developed the land near it, naming the surrounding town Evanston in honor of one of the University’s founders, John Evans. After completing its first building in 1855, Northwestern began classes that fall with two faculty members and 10 students. Sixteen presidents have presided over Northwestern in the years since. The University has grown to include 12 schools and colleges, with additional campuses in Chicago and Doha, Qatar. Learn more at  www.northwestern.edu

Dr. Kaplan went to Medical School at the University of Rochester, NY. Did his Residency at the University of Washington, WA and a Fellowship with the National Cancer Institute/National Institutes of Health. Previously he was Chief Resident, Dept of Medicine: University of Washington, WA; Clinical Associate Professor, University of Washington; Clinical Professor of Medicine Brown University 1977-79; Adjunct Professor of Pharmacy, University of Rhode Island 1977-79; and Assistant Professor of Medicine, University of Washington 1979-1981. His Board Certifications include Internal Medicine and Oncology.

The primary focus of Dr. Kaplan’s research continues to be on breast cancer, although he is also continuing his work in hematological malignancies – cancers affecting blood, bone marrow and lymph nodes – and, more recently, in the area of targeted therapy for genomic mutation.

He has received multiple faculty teaching awards and a Swedish Physician Recognition Award, AOA and Dr. Kaplan was recognized in Seattle Metropolitan magazine’s annual Top Doctors and Nurse Practitioners feature.

As a Seattle-area leader in diagnosis, treatment and recovery since 1932, the Swedish Cancer Institute (SCI) cancer care network offers services to help you fight cancer – and win. Our team includes a host of oncologists – doctors focused exclusively on the care and treatment of cancer, using medication, radiation and other therapies. At our locations in and around the greater Seattle area, we work in a collaborative, multidisciplinary environment that focuses on the patient – not the disease. And even though we use some of the most advanced technologies and procedures, we also offer a wide range of complementary treatments and services that address your psychological, emotional and spiritual needs. The Swedish Cancer Institute has a new weapon in the fight against cancer. It’s called personalized medicine — the biggest news in cancer treatment in years.Learn more at http://www.swedish.org/services/cancer-institute

Janice Lu, MD, PhD is Professor of Medicine and Associate Director of Breast Cancer Research at USC Norris Comprehensive Cancer Center, as well as Breast Cancer Clinical Trials Director, Division of Medical Oncology.

Dr. Janice Lu graduated from Beijing University School of Medicine and completed her Hematology and Medical Oncology fellowship at New York University School of Medicine. She earned her PhD degree from Syracuse University, NY, in Molecular Biology with Dr. David Allis, a pioneer in the foundations of epigenetics at Rockefeller University. She has recently been at UCLA’s Division of Hematology and Oncology as Associate Professor of Medicine , and has previously served as the Director of the Breast Medical Oncology Program at State University of New York at Stony Brook for eight years. She has extensive experience in clinical trials, breast cancer drug development and has led studies as national protocol chair. Her goal is to utilize her science and medical knowledge to work with each patient on a highly individualized basis with state-of-the-art cancer care.

The USC Norris Comprehensive Cancer Center, located in Los Angeles, is a major regional and national resource for cancer research, treatment, prevention and education. More than 200 basic and population scientists, physicians from the faculty of the Keck School of Medicine of USC and several USC professional schools/departments and the College of Letters, Arts and Sciences who are members of the USC Norris Comprehensive Cancer Center investigate the complex origins and progression of cancer, develop prevention strategies and search for cures. The National Cancer Institute (NCI) has designated the USC Norris Comprehensive Cancer Center as one of the nation’s 41 comprehensive cancer centers, a select group of institutions providing leadership in cancer treatment, research, prevention and education. USC Norris Comprehensive Cancer Center has held this designation since 1973, when it was named as one of the first eight comprehensive cancer centers. Learn more at http://uscnorriscancer.usc.edu

Dr. Terry Ng is an Assistant Professor at the University of Ottawa and a Clinician-Investigator in the Department of Medicine. He received his Bachelor of Health Sciences from McMaster University and his MD from the University College Cork. Dr. Ng completed Internal Medicine and Medical Oncology training at the University of Ottawa, followed by an advanced fellowship in Investigational Cancer Therapeutics at the University of Colorado, a National Cancer Institute-designated comprehensive cancer centre.

Dr. Ng’s research interests have focused on treatment-related adverse events. He is the co-Principal Investigator on a multi-center study of early-onset pulmonary toxicity associated with Brigatinib. He is also a co-investigator on a trial funded by the Canadian Breast Cancer Foundation to better address chemotherapy-induced nausea and vomiting. He will be heavily involved in the REaCT pragmatic trials program, which aims to answer real-world, clinical questions in a cost-effective manner.

The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital – one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and annual budget of over $1.2 billion. We rank fourth out of more than 600 Canadian hospitals for competitive, peer-reviewed grants from the prestigious Canadian Institutes of Health Research. The Ottawa Hospital Research Institute’s vision is to give patients and their loved ones new hope through research that is making tomorrow’s health care possible today. The focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, they deliver specialized care to the Eastern Ontario region, but the techniques and research discoveries are adopted around the world.

Dr. Pusztai is Professor of Medicine at Yale University and Chief of the Breast Medical Oncology Section at the Yale Cancer Center. He is also Co-Director of the Cancer Center Genomics and Genetics Program.

He received his medical degree from the Semmelweis University of Medicine in Budapest, and his D.Phil. degree from the University of Oxford in England. He was a Fellow at University of Texas Anderson Cancer Center in Medical Oncology and an intern and resident at University of Rochester St. Mary’s Hospital, Internal Medicine.

His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical and epidemiological risk characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and have shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. His group has also developed new bioinformatics tools to integrate information from across different data platforms in order to define the molecular pathways that are significantly disturbed in individual cancers and could provide the bases for future individualized treatment strategies. He made important contributions to clarify the clinical value of neoadjuvant chemotherapy in different breast cancer subtypes.

Dr. Pusztai is also principal investigator of several clinical trials investigating new drugs and potential response markers. He has published over 200 manuscripts in high impact medical journals and is the Clinical Editor of the British Journal of Cancer, Member of the Scientific Advisory Board of the Breast Cancer Research Foundation, Member of the Breast Cancer Steering Committee of the NCI and Co-Chair of the Trans-ALTTO Committee that oversees the translational research projects of tissues collected during two larger randomized clinical trials (ALTTO and NeoALTTO). He is a member of the BCRF Scientific Advisory Board and the Chair of the Data Safety Monitoring Committee of the OPTIMA trial.

Yale Medical Group (YMG) is one of the largest academic multispecialty group practices in the United States. Our physicians are the clinical faculty for the Yale School of Medicine (YSM). We have over 1,000 practicing physicians, more than 100 specialties and subspecialties, 24/7 on-site and on-call coverage for numerous services, a reputation as a major referral center for Greater New Haven, Connecticut, and New England. We provide compassionate, individualized care to both adult and pediatric patients in a comfortable, professional environment. We listen carefully and provide explanations and answers while encouraging patients to participate in all medical decisions. We work in teams with specially trained nurses, social workers, technologists and other caregivers to support patients and family members before, during and after their visits. Learn more at: http://yalemedicalgroup.org/about/index.aspx#page1

Dr. Elena Shagisultanova, MD, PhD is an Assistant Professor of Medical Oncology at the University of Colorado Anschutz Cancer Center, Aurora, CO. After graduating from medical school and obtaining PhD in biochemistry and molecular genetics in her native Russia, Elena moved to the United States to conduct post-doctoral studies in cancer genetics at the Sanford-Burnham Medical Research Institute (San Diego, CA). Recognizing that her true passion is to become an academic oncologist with a special focus on leading translational and clinical research, Elena finished the University of California San Diego CREST program in clinical research before embarking on her postgraduate clinical training. She completed internal medicine residency training at St. Mary’s Hospital, a University of California San Francisco affiliate (San Francisco, CA), and subsequently served as a chief medical resident. She completed medical oncology and hematology fellowship training at Fox Chase Cancer Center (Philadelphia, PA), where she continued translational cancer research at the laboratories of Dr. Erica Golemis and Dr. Wafik El-Deiry. At Fox Chase, Elena became deeply committed to become breast cancer clinician and researcher; this decision was influenced by her work with clinical mentors – Dr. Mary Daily, Dr. Lori Goldstein, and Dr. Robert Carlson. After completion of her fellowship, Elena moved to Colorado and joined the University of Colorado Young Women Breast Translational Research Program lead by Dr. Virginia Borges. Elena is now specializing in the field of young women breast cancer, and works both in the clinic and the lab – seeing patients, conducting clinical trials and translational research of novel targeted agents – with the goal to deliver the best care for her patients. She is board certified in internal medicine, hematology and medical oncology. She is a member of the American Society of Clinical Oncology and American Association for Cancer Research.

The University of Colorado Cancer Center is the Rocky Mountain region’s only National Cancer Institute-designated comprehensive cancer center. NCI has given only 40 cancer centers this designation, deeming membership as “the best of the best.” Headquartered on the University of Colorado Denver Anschutz Medical Campus, UCCC is a consortium of three state universities (Colorado State University, University of Colorado at Boulder and University of Colorado Denver) and six institutions (AMC Cancer Research Center, The Children’s Hospital, Denver Health, Denver VA Medical Center, National Jewish Health and University of Colorado Hospital). Together, our 400+ members are working to ease the cancer burden through cancer care, research, education and prevention and control. Learn more at  www.ucdenver.edu.

Dr. Alison Stopeck is Chief, Division of Hematology/Oncology, Professor, Department of Internal Medicine Associate & Director for Translational Research, Stony Brook Cancer Center. She obtained her MD degree from Columbia University College of Physicians and Surgeons, NY. She did her residency in Internal Medicine, at Columbia Presbyterian Medical Center, NY and a Fellowship in Hematology/Oncology at Cornell University Medical College, NY. She is board certified from the American Board of Internal Medicine, subspecialties in Hematology and Medical Oncology.

As for Dr. Stopeck’s research interests, she is currently involved in clinical trials targeting patients with breast cancer, who are receiving chemotherapy. Dr. Stopeck is the principal or collaborating investigator on multiple clinical trials involving novel agents, prognostic markers and predictors of response in breast cancer patients, as well as supportive care and survivorship issues in breast cancer. Dr. Stopeck has numerous publications in medical journals and textbooks, including the New England Journal of Medicine and the Journal of Clinical Oncology. She acts as an Associate Editor for the American Journal of Medicine and is an ad hoc reviewer for several journals. She has been a funded investigator from the NCI for over a decade.

Her honors and awards include:

• Who’s Who in America-Professional Edition
• 2014 – Best Doctors in America, Woodward/White, Inc.
• 2009 – America’s Top Doctor for Cancer

Long Island’s premier academic medical center, Stony Brook Medicine represents Stony Brook University’s entire medical enterprise and integrates Stony Brook’s health-related initiatives: education, research and patient care. It encompasses Stony Brook University Hospital, the five Health Sciences schools � Dental Medicine, Health Technology and Management, Medicine, Nursing and Social Welfare � as well as the major centers and institutes, programs and more than 50 community-based healthcare settings throughout Suffolk County. Learn more at https://www.stonybrookmedicine.edu/patientcare

Kari Wisinski, MD is an Assoc. Professor (CHS) at Univ of Wisconsin School of Medicine Hematology/Oncology Division

Dr. Kari Wisinski is a medical oncologist with UW School of Medicine and Public Health and the Carbone Cancer Center in Madison, Wisconsin, and is a member of the UW Health Breast Center.

Dr. Wisinski obtained her medical degree from Washington University School of Medicine in 2001. She then completed internal medicine residency at the University of Colorado Health Sciences Center, followed by a combined hematology and oncology fellowship at Northwestern University. She is board certified in hematology and medical oncology.

In 2008, she joined the University of Wisconsin School of Medicine and Public Health in the Division of Hematology/Oncology. Her clinical expertise involves the care of patients with breast cancer. Dr. Wisinski’s research is focused on designing and running clinical trials testing targeted agents for breast cancer, with a particular focus on phase I trials and triple negative breast cancer. Dr. Wisinski is also co-Director of the Wisconsin Oncology Network, a statewide medical oncology research group and co-Leader of the Big Ten Cancer Research Consortium Breast Cancer Working Group.

UW Health consists of the academic health care entities of the University of Wisconsin-Madison: UW Medical Foundation, UW Hospital and Clinics and UW School of Medicine and Public Health. UW Health is also home to American Family Children’s Hospital and UW Carbone Cancer Center. Our expert doctors are at the forefront of research, developing new treatments and training the next generation of physicians. Together with other health care professionals, they serve the health needs of Wisconsin, and beyond. By combining our resources into one system, we are able to offer a network of primary and specialty care clinics throughout southcentral Wisconsin and beyond.

This network provides access to more than 1,200 primary and specialty care physicians who are leaders in their fields, as well as the opportunity to be treated at University of Wisconsin Hospital and Clinics, frequently cited in published rankings of the finest academic medical centers. Learn more at:  http://www.uwhealth.org/about-uwhealth/main/10730

Dr. Douglas Yee is Professor of Medicine and Pharmacology and the Cancer Center Director at the Masonic Cancer Center, University of Minnesota. He received his MD in 1981 from the University of Chicago Pritzker School of Medicine. He received his internal medicine training and was Chief Medical Resident at the University of North Carolina. His medical oncology training was done at the National Cancer Institute in Bethesda, Maryland. Prior to coming to Minnesota, he held faculty positions at Georgetown University Medical Center and the University of Texas Health Science Center at San Antonio. Dr. Yee holds the John H. Kersey Chair in Cancer Research. He was previously co-leader of the Women’s Cancer Program. Dr Yee specializes in Medical Oncology and Breast Cancer.

The Masonic Cancer Center was founded in 1991. It is part of the University’s Academic Health Center, which also includes the Medical School, School of Dentistry, School of Nursing, College of Pharmacy, School of Public Health and College of Veterinary Medicine. The Masonic Cancer Center’s research partners include the University’s Stem Cell Institute, Center for Immunology, the Center for Magnetic Resonance Imaging, the Clinical and Translational Science Center and the Physical Sciences in Oncology Center; and its clinical research and treatment partners include University of Minnesota Health Cancer Care, University of Minnesota Medical Center, and University of Minnesota Masonic Children’s Hospital. The Masonic Cancer Center, University of Minnesota is designated by the National Cancer Institute as a comprehensive cancer center. The NCI awards this highest-level designation only to institutions that make ongoing, significant advances in cancer research, treatment, and education. Masonic Cancer Center is part of a 47-member group of cancer centers in the United States to hold the comprehensive designation, and the only one in the greater Twin Cities region. Learn more at: http://www.med.umn.edu/about